Maze Therapeutics, Inc. (MAZE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.21+1.31%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Maze Therapeutics is managing to reduce its operating losses, cutting them from $36.47 million in 2025-Q2 to $26.55 million in 2026-Q1. The company has beaten earnings estimates in recent quarters, showing some operational progress. Despite losses, the stock has gained about 29% over the past 21 days, reflecting improving investor sentiment.
Maze remains unprofitable with negative earnings expected through 2027. The CEO selling shares and CFO departure raise concerns about management confidence. Analysts expect revenue to decline by over 40% next year, signaling weak business prospects.
The market currently prices Maze about 42% below our valuation level and expects revenue to decline by 42% next year. Our view aligns with the market on weak near-term revenue but sees some potential for loss reduction that is not fully reflected.
Breaks if: Operating losses worsen beyond -$26.55 million in any quarter after 2026-Q1
Breaks if: Additional senior management departures or significant insider selling
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is weakened due to recent financial performance dropping significantly within its industry.
The market appears to price MAZE as a cheap option compared to its peers, with a slight expectations gap. However, the valuation is justified given the company's loss-making status and recent performance.
Management is on track with clinical trials for key products, which could support future growth. However, recent financial performance has been weak, and the company operates in a high-miss-rate industry, adding to near-term risks.
The thesis hinges on management's ability to execute on clinical milestones and maintain a strong cash position. Additionally, external factors like sector performance and economic conditions will play a crucial role in shaping outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates a weakened reason to own the company. The market reaction has been muted, with the price moving only modestly compared to the S&P.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue declines more than 42% in 2026 or continues falling in 2027
Over the next 1 to 3 years, MAZE's prospects depend on successful clinical advancements and broader market conditions. Not investment advice.